Clinical Roundup Researchers “turbocharge” immune cells to attack prostate cancer March 27, 2026Vol.52 No.12
Clinical Roundup Dual-targeting approach improves immunotherapy response in glioblastoma, MD Anderson study finds March 27, 2026Vol.52 No.12
Clinical Roundup GPSai AI algorithm may help identify and correct misdiagnoses of cancer March 27, 2026Vol.52 No.12
Drugs & Targets FDA and EC approve Opdivo IO combinations in classical Hodgkin Lymphoma March 27, 2026Vol.52 No.12
Drugs & Targets FDA approves relacorilant + nab-paclitaxel for platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer March 27, 2026Vol.52 No.12
Drugs & Targets FDA approves label update to accelerate thaw time for Adstiladrin gene therapy for NMIBC March 27, 2026Vol.52 No.12
NCI Hoping to hit a $200M target, NCI and FNIH develop a plan for advancing cancer vaccinesNCI Director Letai: “How aggressive can we be?” March 20, 2026Vol.52 No.11By Claire Marie Porter
NCI A new working group will conduct site visits and advise NCAB and NCI director on cancer center grants March 20, 2026Vol.52 No.11By Paul Goldberg
NCI Letai: “From this point forward, it really is much more like business as usual at the NCI.” March 20, 2026Vol.52 No.11By Jacquelyn Cobb
Cancer Policy The reconstitution of ACIP and changes to CDC’s childhood vaccine schedule were likely illegal, judge rules March 20, 2026Vol.52 No.11By Sara Willa Ernst
